Research

Acute Lymphoblastic Leukemia High Risk B – Precursor Study – Phase III

Protocol Description

The goal of this Children's Oncology Group Phase III study is to determine whether modifying the chemotherapy treatment given within specific stages could increase the cure rate of high-risk acute lymphoblastic leukemia (ALL) without increasing the side effects of therapy. Participants will receive the therapy that is considered standard for high-risk ALL patients, but some will be randomly selected to receive standard therapy with 2 drug modifications, resulting in a total of 4 treatment groups. This international study will enroll approximately 2,300 participants with 40 from Children’s Hospital of Pittsburgh of UPMC.

Eligibility Criteria

This international group study will be enrolling patients between the ages of 1 and 30 years who have been recently diagnosed with high-risk ALL.
Boys: Age 1 and up
Girls: Age 1 and up

Requirements
Participants will be given various physical exams, organ function tests and medical procedures throughout the length of the study that are part of regular care for patients with high-risk ALL. Participants will be randomly assigned to a treatment group.
Visits: Number will depend on course of treatment
Duration: 2.5 to 3.5 years

Status: Open for Enrollment

Source of Support
Children’s Oncology Group (Study AALL0232)
National Cancer Institute

Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health